Roche Holding AG (ROP.SW)

Roche Holding AG (ROP.SW) — VMCI valuation read

Headline read on ROP.SW: VMCI of 55/100 versus a Healthcare sector median of 50. The 5-point above-median position is what makes Roche Holding AG a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on ROP.SW: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on ROP.SW: value (ROP.SW trades at 25.0x earnings, 39% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of -0.3x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

ROP.SW rose 1.1% over the trailing 7 days, with a -13.0% read on a 30-day basis.